Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals'

Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune 
Checkpoints Including Peregrine Pharmaceuticals' Bavituximab
PS Target 
Symposium's Lead Presenter Dmitry Gabrilovich, M.D., Ph.D.,
Accomplished Clinical Immunologist to Be Accompanied by Panel of Key
Thought Leaders From Fields of Oncology, Immunology and Lung Cancer;
Peregrine's Lead Product Candidate Bavituximab Represents the First
in a New Class of Immunotherapeutics That Targets the Novel PS
Upstream Checkpoint 
TUSTIN, CA -- (Marketwired) -- 10/15/13 --  Peregrine Pharmaceuticals
(NASDAQ: PPHM) today announced that participants at the International
Association for the Study of Lung Cancer's (IALSC) 15th World
Conference on Lung Cancer to be held October 27 - 30, 2013 in Sydney,
Australia will discuss novel immunotherapy checkpoint inhibitors
including Peregrine's novel target phosphatidylserine (PS). The
conference is the world's largest meeting dedicated to lung cancer
and other thoracic malignancies and brings together more than 5,000
delegates from across the medical and scientific professional
spectrums from more than 100 countries.  
The symposium titled: "Immune Checkpoints in the Tumor Environment:
Novel Targets and the Clinical Promise of Combined Immunotherapies"
will focus on the identification of new immunosuppressive targets in
tumors and the potential for improved clinical outcomes through
multiple immune checkpoint blockade. The event will take place in
Parkside Ballroom B, Conference Level 1 of the Sydney Convention and
Exhibition Centre on Monday, October 28th from 7:00-8:00 AM UTC. The
program for the symposium is as follows: 
Moderator: 
 Scott J. Antonia, M.D., Ph.D.
 Associate Professor in
the Department of Interdisciplinary Oncology and the Co-Program
Leader of the Immunology Program at the H. Lee Moffitt Cancer Center,
Tampa, Florida 
Presentations: 
 Dmitry I. Gabrilovich, M.D., Ph.D.
 Professor in
Cancer Research and Program Leader, Translational Tumor Immunology at
The Wistar Institute, Philadelphia, Pennsylvania
 "Myeloid-Derived
Suppressor Cells as Negative Regulator of Immune Responses in Cancer" 
Rolf A. Brekken, Ph.D.
 Effie Marie Cain Research Scholar in
Angiogenesis Research and an Associate Professor, in the Departments
of Surgery and Pharmacology at the Hamon Center for Therapeutic
Oncology, University of Texas Southwest Medical Center, Dallas,
Texas
 "Engagement of Phosphatidylserine (PS) by PS-Targeting
Antibodies Blocks a Global Immunosuppressive Checkpoint in the Tumor
Microenvironment Inducing Multiple Downstream Anti-Tumor Response
Mechanisms" 
David E. Gerber, M.D.
 Associate Professor of Internal Medicine in
the Hematology-Oncology Division at the University of Texas
Southwestern Medical Center, Dallas, Texas
 "Clinical Experience and
Prospects with Checkpoint Immunotherapy in Lung Cancer" 
Peregrine will also be hosting convention visitors at Exhibit Booth
#702.  
"This conference brings together thought leaders from all over the
world and in particular this symposium will bring together a set of
key opinion leaders to focus on the current understanding of tumor
immune checkpoints and the therapeutic potential of combining
upstream and downstream immune checkpoint blockers. We are pleased
that part of this discussion will focus on the recent data validating
bavituximab's PS as global immunosuppressive checkpoint," said
Kerstin Menander, M.D., Ph.D., head of medical oncology at Peregrine
Pharmaceuticals. "Drs. Gabrilovich and Antonia are recognized leaders
in the immunotherapy community and we are particularly pleased that
they agreed to participate in the symposium. Their insights into new
approaches for immunotherapy combination therapy studies will be
extremely valuable as we continue to advance our bavituximab program
toward its first such clinical trials."  
About the Presenters  
Scott J. Antonia, M.D., Ph.D.
 Dr. Antonia is currently the
Department Chair and Program Leader of the Thoracic Oncology
Department Associate Professor in the Department of Interdisciplinary
Oncology and Program Leader of the Immunology Program at the H. Lee
Moffitt Cancer Center and Research Institute in Tampa, Florida. He is
also a Professor of Oncology at the University of South Florida
College of Medicine in Tampa. Prior to being named chair of Thoracic
Oncology in 2010, he was associate chairman of the Sarcoma
Department. He joined the Moffitt Cancer Center in 1994. Dr. Antonia
received his M.D. and his Ph.D. in Immunology from the University of
Connecticut Health Center in Farmington, Connecticut. In addition, he
completed an internal medicine residency at Yale University School of
Medicine and pursued additional training at Yale through a medical
oncology fellowship and post-doctoral fellowship in Immunobiology.
Dr. Antonia's work focuses on translational research. Using his
molecular biology and cellular background in the development of
immunotherapeutic strategies for the treatment of cancer patients, he
has developed strategies designed to thwart the immunosuppressive
mechanisms used by tumors to evade T-cell mediated rejection. Dr.
Antonia has published papers in several peer-reviewed journals,
including Science, Clinical Cancer Research, Current Opinions in
Oncology, and Cancer Research.  
Dmitry I. Gabrilovich, M.D., Ph.D.
 Dr. Gabrilovich is currently the
Christopher M. Davis Professor in Cancer Research and Program Leader,
Translational Tumor Immunology at The Wistar Institute, Philadelphia,
Pennsylvania. The Wistar Institute is the nation's first independent
institution devoted to medical research and training and has been
designated a National Cancer Institute Cancer Center in basic
research. Dr. Gabrilovich's lab is focused on understanding the
mechanisms of tumor-associated immunosuppression as well as on the
development of new effective cancer immunotherapeutics. Prior to
joining Wistar, Dr. Gabrilovich was the Robert Rothman Endowed Chair
in Cancer Research and Head, Section of Dendritic Cell Biology at the
H. Lee Moffitt Cancer Center in the Department of Immunology and a
Professor of Oncologic Sciences and Molecular Medicine at the
University of South Florida in Tampa, Florida. Prior to this, Dr.
Gabrilovich was a Research Fellow at the Imperial College in London,
United Kingdom and at the University of Texas Southwestern Medical
Center in Dallas, Texas. Dr. Gabrilovich earned his M.D. from
Kabardino-Balkarian State University Medical School in Nalchik,
Russia and his Ph.D. in Immunology from the Central Institute of
Epidemiology in Moscow. He has over 25 years of experience, extensive
knowledge in this field and has more than 180 peer-reviewed
publications. 
Rolf A. Brekken, Ph.D.
 Dr. Brekken is the Effie Marie Cain Research
Scholar in Angiogenesis Research and an Associate Professor, in the
Departments of Surgery and Pharmacology, a Principal Investigator in
the Hamon Center for Therapeutic Oncology Research, and a member of
Simmons Comprehensive Cancer Center, University of Texas Southwest
Medical Center in Dallas, Texas. Dr. Brekken received his Bachelor of
Arts degree from Luther College in Decorah, Iowa and his PhD (Cell
and Molecular Biology) from UT Southwestern Graduate School of
Biomedical Sciences. He completed his postdoctoral training in the
Department of Vascular Biology at the Hope Heart Institute in
Seattle, Washington where he studied how the extracellular matrix
contributes to vascular function in and growth of tumors. He is an
author on over 100 peer reviewed scientific papers and is a senior
editor of Cancer Research. Research in the Brekken laboratory is
funded by the NCI, the American Cancer Society, the Mary Kay
Foundation and CPRIT as well as several biopharmaceutical companies.  
David E. Gerber, M.D.
 Dr. Gerber is currently an Associate Professor
of Internal Medicine in the Hematology-Oncology Division at the
University of Texas Southwestern Medical Center in Dallas, Texas
where he joined the faculty in 2007. Dr. Gerber earned his M.D. from
Cornell University Medical College in New York, New York, and
completed his internship and residency in Internal Medicine at the
University of Texas Southwestern Medical Center in Dallas, Texas. He
completed his fellowship in medical oncology at Johns Hopkins
University School of Medicine in Baltimore, Maryland. Dr. Gerber is
board certified in Internal Medicine and Medical Oncology. Dr. Gerber
is particularly interested in lung cancer and is highly active in
related research. His research has generated over 40 peer-reviewed
publications. He has authored two books and 12 book chapters on this
topic and his studies have contributed to invitations to lecture both
nationally and internationally.  
This symposium will not be webcast. 
About Peregrine Pharmaceuticals, Inc. 
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative monoclonal antibodies in clinical trials
focused on the treatment and diagnosis of cancer. The company is
pursuing multiple clinical programs in cancer with its lead
immunotherapy candidate bavituximab and novel brain cancer agent
Cotara(R). Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com. 
Contact: 
Christopher Keenan or Jay Carlson 
Peregrine Pharmaceuticals
(800) 987-8256 
info@peregrineinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.